Grant: Discovery Launch Supplement
University of Guelph
$12,500.00
Engineering Highly Sensitive Bioassay Platforms with 3D Metal-Nanomaterial-Enhanced Fluorescence
EF 2024-25
Résumé
Technologies for early diagnostics are vital for improving patient outcomes in complex diseases such as cancer and cardiovascular diseases, potentially saving tens of millions of lives every year globally. One promising avenue for early disease detection is the use of extracellular vesicles (EVs), tiny vesicles released by cells into body fluids like blood and urine. EVs carry biomolecules similar to their cells of origin and play crucial roles in disease formation and progression, making them valuable for disease management. Detecting and analyzing EV contents, especially EV proteins in biofluids, hold significant potential for early diagnostics. Moreover, EVs can serve as a natural therapeutic platform for drug delivery, with low immunogenicity and tumorigenicity, and can promote tissue regeneration and wound healing. Therefore, studying EVs presents an exciting opportunity for ground-breaking advances for better healthcare.
However, current technologies face considerable challenges in detecting and measuring EV content in body fluids, mainly due to limitations in sensitivity and scalability. The gold standard method, enzyme-linked immunosorbent assay (ELISA), falls short in sensitivity for early disease detection and is unsuitable for multiplexed analysis. Although new technologies, such as those based on metal-enhanced fluorescence, have shown promise, their high technical complexity hinders wider applications in research communities.
In this research program, we aim to develop novel and highly promising technologies for sensitive, accurate, and multiplexed EV protein measurements in biological samples. Our approach integrates metal nanomaterial into biocompatible polymers, providing unique platforms capable of detecting EV proteins at very low concentrations. This breakthrough has the potential to enable earlier disease diagnostics, leading to improved patient outcomes. Furthermore, by enhancing the accuracy of EV protein measurements, our research will enable more reliable quantitative analysis of biological samples. Another significant advantage of our proposed technologies is their ease of implementation in research labs with basic setups, allowing for rapid technology transfer and widespread availability to researchers and diagnostic labs on a broader scale.
The impact of our research extends beyond the laboratory, as it will provide powerful tools for highly sensitive analysis of complex biosystems to help advance biological and biomedical research. By addressing the current limitations and challenges in EV protein measurement, our program seeks to revolutionize early diagnostics, potentially transforming healthcare outcomes. The funding of this research program will not only contribute to Canada's worldwide leading role in biotechnology but also make significant strides toward improving patient care on a global scale.
Programme
Discovery Launch Supplement
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
DGECR-2024-00482
Name nom
Li, Huiyan
Department département
School of Engineering
Organization id
24
Institution établissement
University of Guelph
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2024
Award amount
12500
Program id
DGECR
Program name en
Discovery Launch Supplement
Program name fr
Supplément Tremplin vers la découverte
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1511
Committee name en
Materials and Chemical Engineering
Committee name fr
Génie chimique et des matériaux
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1802
Research subject group en
Chemical engineering
Research subject group fr
Génie chimique
Research subject en
Biochemical engineering
Research subject fr
Génie biochimique
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Engineering Highly Sensitive Bioassay Platforms with 3D Metal-Nanomaterial-Enhanced Fluorescence
Keywords
bioassay development; hydrogel; nanomaterial; bioassay sensitivity; extracellular vesicles; proteins; multiplexing capability; metal enhanced fluorescence; biosensing
Application summary
Technologies for early diagnostics are vital for improving patient outcomes in complex diseases such as cancer and cardiovascular diseases, potentially saving tens of millions of lives every year globally. One promising avenue for early disease detection is the use of extracellular vesicles (EVs), tiny vesicles released by cells into body fluids like blood and urine. EVs carry biomolecules similar to their cells of origin and play crucial roles in disease formation and progression, making them valuable for disease management. Detecting and analyzing EV contents, especially EV proteins in biofluids, hold significant potential for early diagnostics. Moreover, EVs can serve as a natural therapeutic platform for drug delivery, with low immunogenicity and tumorigenicity, and can promote tissue regeneration and wound healing. Therefore, studying EVs presents an exciting opportunity for ground-breaking advances for better healthcare.
However, current technologies face considerable challenges in detecting and measuring EV content in body fluids, mainly due to limitations in sensitivity and scalability. The gold standard method, enzyme-linked immunosorbent assay (ELISA), falls short in sensitivity for early disease detection and is unsuitable for multiplexed analysis. Although new technologies, such as those based on metal-enhanced fluorescence, have shown promise, their high technical complexity hinders wider applications in research communities.
In this research program, we aim to develop novel and highly promising technologies for sensitive, accurate, and multiplexed EV protein measurements in biological samples. Our approach integrates metal nanomaterial into biocompatible polymers, providing unique platforms capable of detecting EV proteins at very low concentrations. This breakthrough has the potential to enable earlier disease diagnostics, leading to improved patient outcomes. Furthermore, by enhancing the accuracy of EV protein measurements, our research will enable more reliable quantitative analysis of biological samples. Another significant advantage of our proposed technologies is their ease of implementation in research labs with basic setups, allowing for rapid technology transfer and widespread availability to researchers and diagnostic labs on a broader scale.
The impact of our research extends beyond the laboratory, as it will provide powerful tools for highly sensitive analysis of complex biosystems to help advance biological and biomedical research. By addressing the current limitations and challenges in EV protein measurement, our program seeks to revolutionize early diagnostics, potentially transforming healthcare outcomes. The funding of this research program will not only contribute to Canada's worldwide leading role in biotechnology but also make significant strides toward improving patient care on a global scale.